Literature DB >> 17458400

Pulmonary arterial hypertension: evaluation and management.

Anne V LaRaia1, Aaron B Waxman.   

Abstract

Pulmonary arterial hypertension (PAH), a rare disease involving the pulmonary vascular circuit, is defined as an elevation in pulmonary arterial pressures and is characterized by symptoms of dyspnea, chest pain, and syncope. If left untreated, the disease carries a high mortality rate, with the most common cause of death being decompensated right heart failure. Over the past 5 years, there have been significant advances in this field in regards to understanding the pathogenesis, diagnosis, and classification of PAH. The availability of newer drugs has resulted in a radical change in the management of this disease with significant improvement in both quality of life and mortality. Ongoing research promises to lead to a more comprehensive understanding of the genetics, etiology, and pathogenesis of pulmonary arterial hypertension, which may ultimately translate into more effective therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458400     DOI: 10.1097/SMJ.0b013e31802f2ff1

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.

Authors:  Leanda Vengethasamy; Aurélie Hautefort; Birger Tielemans; Catharina Belge; Frédéric Perros; Stijn Verleden; Elie Fadel; Dirk Van Raemdonck; Marion Delcroix; Rozenn Quarck
Journal:  Pflugers Arch       Date:  2016-11-06       Impact factor: 3.657

Review 2.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

Review 3.  Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.

Authors:  Patrick Crosswhite; Zhongjie Sun
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.